PMID- 10773701
OWN - NLM
STAT- MEDLINE
DCOM- 20000627
LR  - 20171101
IS  - 1018-8665 (Print)
IS  - 1018-8665 (Linking)
VI  - 200
IP  - 2
DP  - 2000
TI  - Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report 
      of three cases.
PG  - 129-31
AB  - BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE) is a subset of lupus 
      erythematosus characterized mainly by prominent photoaggravated cutaneous 
      manifestations. Standard therapies for SCLE include topical or systemic steroids 
      and antimalarial drugs. Both methods show limited efficacy in clearing cutaneous 
      lesions and occasionally produce serious side effects. AIM: To assess the 
      efficacy of cefuroxime axetil, an oral cephalosporin with antibacterial and 
      immunosuppressive activity, in patients with SCLE. METHODS: Three patients with 
      SCLE were treated with cefuroxime axetil at a daily dose of 500 mg for 30-60 
      days. RESULTS: In all patients complete clearing of skin lesions was achieved and 
      no side effects were observed. CONCLUSION: We suggest that long-term cefuroxime 
      axetil administration might be an alternative treatment for patients with SCLE 
      skin lesions.
CI  - Copyright 2000 S. Karger AG, Basel.
FAU - Rudnicka, L
AU  - Rudnicka L
AD  - Department of Dermatology, CSK MSWiA, Warsaw, Poland. lidiarud@czsz.mswia.gov.pl
FAU - Szymanska, E
AU  - Szymanska E
FAU - Walecka, I
AU  - Walecka I
FAU - Slowinska, M
AU  - Slowinska M
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Cephalosporins)
RN  - O1R9FJ93ED (Cefuroxime)
RN  - Z49QDT0J8Z (cefuroxime axetil)
SB  - IM
MH  - Adult
MH  - Cefuroxime/*analogs & derivatives/therapeutic use
MH  - Cephalosporins/*therapeutic use
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*drug therapy/pathology
MH  - Middle Aged
MH  - Skin/pathology
EDAT- 2000/04/25 09:00
MHDA- 2000/07/06 11:00
CRDT- 2000/04/25 09:00
PHST- 2000/04/25 09:00 [pubmed]
PHST- 2000/07/06 11:00 [medline]
PHST- 2000/04/25 09:00 [entrez]
AID - 18345 [pii]
AID - 10.1159/000018345 [doi]
PST - ppublish
SO  - Dermatology. 2000;200(2):129-31. doi: 10.1159/000018345.